Liquidia Technologies

Primary contact

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. This novel process optimizes the performance of existing or new therapeutics, whether they are based on small molecules, peptides or biologics. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply the PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration.
Primary contact

Funding 💰

Total $99.3M
Select investors New Enterprise Associates, Canaan Partners, GlaxoSmithKline, Morningside Group, Pappas Ventures, Bill & Melinda Gates Foundation, Pharmaceutical Product Development, Xeraya Capital, National Institute of Standards and Technology
Last update: May 14, 2018